These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17345073)

  • 1. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.
    Sriwiriyajan S; Mahatthanatrakul W; Ridtitid W; Jaruratanasirikul S
    Eur J Clin Pharmacol; 2007 May; 63(5):479-83. PubMed ID: 17345073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between efavirenz and ketoconazole in rats.
    Saadeddin A; Peris JE
    Xenobiotica; 2009 Feb; 39(2):135-9. PubMed ID: 19255939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
    Pillai VC; Parise RA; Christner SM; Rudek MA; Beumer JH; Venkataramanan R
    J Clin Pharmacol; 2014 Nov; 54(11):1272-9. PubMed ID: 24846165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
    Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
    Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
    N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter.
    Wu CJ; Lee HC; Yang YL; Chang CM; Chen HT; Lin CC; Lee NY; Chu WL; Hsieh LY; Wang YL; Lauderale TL; Tseng FC; Ko NY; Ko WC; Lo HJ
    Clin Microbiol Infect; 2012 May; 18(5):485-90. PubMed ID: 21939471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of the interaction between itraconazole and nevirapine.
    Jaruratanasirikul S; Sriwiriyajan S
    Eur J Clin Pharmacol; 2007 May; 63(5):451-6. PubMed ID: 17342480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
    Kovarik JM; Dole K; Riviere GJ; Pommier F; Maton S; Jin Y; Lasseter KC; Schmouder RL
    J Clin Pharmacol; 2009 Feb; 49(2):212-8. PubMed ID: 19118083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
    Pillai VC; Venkataramanan R; Parise RA; Christner SM; Gramignoli R; Strom SC; Rudek MA; Beumer JH
    Drug Metab Dispos; 2013 Oct; 41(10):1843-51. PubMed ID: 23913028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
    Kovarik JM; Huang HL; Slade A; Sfikas N; Chandler PA
    Br J Clin Pharmacol; 2009 Sep; 68(3):381-5. PubMed ID: 19740395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.
    Ye M; Wang L; Fu Q; Zhu Z; Li P; Li T
    HIV Clin Trials; 2010; 11(4):230-7. PubMed ID: 20974578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.
    Nanzigu S; Eriksen J; Makumbi F; Lanke S; Mahindi M; Kiguba R; Beck O; Ma Q; Morse GD; Gustafsson LL; Waako P
    HIV Med; 2012 Apr; 13(4):193-201. PubMed ID: 22107359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
    Calderón MM; Penzak SR; Pau AK; Kumar P; McManus M; Alfaro RM; Kovacs JA
    Clin Infect Dis; 2016 Apr; 62(8):1036-1042. PubMed ID: 26797214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
    JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
    Herranz U; Rusca A; Assandri A
    Int J Clin Pharmacol Ther; 2001 Mar; 39(3):102-9. PubMed ID: 11396749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.